LEXINGTON, Mass., Jan. 27 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that a copy of its 2008 Annual Report has been posted on and is available at the Company's website at www.indevus.com. In addition, the Company's stockholders may obtain a free hard copy of the Annual Report by contacting the Company's Investor Relations department at (781) 861-8444 or by mailing written requests to Indevus Pharmaceuticals, Inc., Attention Investor Relations, 33 Hayden Ave., Lexington, Massachusetts 02421.
The Company's common stock is listed and traded on the NASDAQ Global Market under the symbol "IDEV."
About Indevus Pharmaceuticals
Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering.
Contact: Michael W. Rogers EVP and Chief Financial Officer (781) 861-8444 Robin L. DeCarlo Sr. Director, Corporate Communications (781) 402-3405
|SOURCE Indevus Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved